Spiriva Respimat - (2.5 mcg per actuation; Spray, Metered; Inhalation Aerosol)

Generic Name	Tiotropium Bromide	Innovator	Boehringer Ingelheim
Dosage	2.5 mcg per actuation; Spray, Metered; Inhalation Aerosol	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	None	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	SPIRIVA RESPIMAT is an anticholinergic indicated for:  The long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), and for reducing COPD exacerbations  The long-term, once-daily, maintenance treatment of asthma in patients 6 years of age and older.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
****** ******	*** / *********	*** **, ****	********* ** ****** ** ******	****	******* *** **** *** *** ****

Chronology Of Events